Ammonium glycyrrhizinate-loaded niosomes as a potential nanotherapeutic system for anti-inflammatory activity in murine models

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 635-651

  Marianecci, Carlotta ^a   Rinaldi, Federica ^a   Di Marzio, Luisa ^b   Mastriota, Marica ^c   Pieretti, Stefano ^c   Celia, Christian ^b,d   Paolino, Donatella ^e   Iannone, Michelangelo ^f,g   Fresta, Massimo ^e   Carafa, Maria ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^e UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^f Environmental Epidemiology Center   (Italy)

^g CNR   (Italy)

Author keywords

Ammonium glycyrrhizinate; Cytotoxicity; Inflammation; Niosomes; pH sensitivity

Indexed keywords

1,6 DIPHENYL 1,3,5 HEXATRIENE; AMMONIUM GLYCYRRHIZATE; CELLULOSE; CHOLESTEROL; CHOLESTEROL HYDROGEN SUCCINATE; GLYCYRRHIZIC ACID; NIOSOME; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; LIPOSOME; NANOCAPSULE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANISOTROPY; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSAGE FORM COMPARISON; EDEMA; FIBROBLAST; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VIVO STUDY; LIGHT SCATTERING; LIPID BILAYER; MALE; MOLECULAR STABILITY; MOUSE; NOCICEPTION; NONHUMAN; PAIN; PH; PHYSICAL CHEMISTRY; SERUM; ANIMAL; CHEMISTRY; CYTOTOXICITY; DIFFUSION; INFLAMMATION; NIOSOMES; PH SENSITIVITY; SYNTHESIS; TREATMENT OUTCOME;

AMMONIUM GLYCYRRHIZINATE; CYTOTOXICITY; INFLAMMATION; NIOSOMES; PH SENSITIVITY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DIFFUSION; EDEMA; GLYCYRRHIZIC ACID; LIPOSOMES; MALE; MICE; NANOCAPSULES; PAIN; TREATMENT OUTCOME;

EID: 84893447134     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S55066     Document Type: Article

References (68)

1. Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 1998;172(1–2):33–70.
2. Terzano C, Allegra L, Alhaique F, Marianecci C, Carafa M. Non phospholipid vesicles for pulmonary glucocorticoid delivery. Eur J Pharm Biopharm. 2005;59(1):57–62.
3. Di Marzio L, Esposito S, Rinaldi F, Marianecci C, Carafa M. Polysorbate 20 vesicles as oral delivery system: in vitro characterization. Colloids Surf B Biointerfaces. 2013;104:200–206.
4. Di Marzio L, Marianecci C, Rinaldi F, Esposito S, Carafa M. Deformable surfactant vesicles loading ammonium glycyrrhizinate: characterization and in vitro permeation studies. Lett Drug Des Discov. 2012;9(5):494–499.
5. Marianecci C, Rinaldi F, Di Marzio L, et al. Polysorbate 20 vesicles as multi-drug carriers: in vitro preliminary evaluations. Lett Drug Des Discov. 2013;10(3):212–218.
6. Mahale NB, Thakkar PD, Mali RG, Walunj DR, Chaudhari SR. Niosomes: novel sustained release nonionic stable vesicular systems – an overview. Adv Colloid Interface Sci. 2012;183–184:46–54.
7. Marianecci C, Rinaldi F, Ingallina C, et al. Smart magnetic nanovesicles for theranostic application: preparation and characterization. Nuovo Cimento C. 2013;36C(2):103–110.
8. Di Marzio L, Marianecci C, Petrone M, Rinaldi F, Carafa M. Novel pH-sensitive non-ionic surfactant vesicles: comparison between Tween 21 and Tween 20. Colloids Surf B Biointerfaces. 2011;82(1):18–24.
9. Carafa M, Di Marzio L, Marianecci C, et al. Designing novel pH-sensitive non-phospholipid vesicle: characterization and cell interaction. Eur J Pharm Sci. 2006;28(5):385–393.
10. Baronzio G, Schwartz L, Kiselevsky M, et al. Tumor interstitial fluid as modulator of cancer inflammation, thrombosis, immunity and angiogenesis. Anticancer Res. 2012;32(2):405–414.
11. Wiig H. Pathophysiology of tissue fluid accumulation in inflammation. J Physiol. 2011;589 Pt 12:2945–2953.
12. Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev. 2012;64 Suppl:302–315.
13. Lee ES, Gao Z, Bae YH. Recent progress in tumor pH targeting nanotechnology. J Control Release. 2008;132(3):164–170.
14. Huang S, Shao K, Kuang Y, et al. Tumor targeting and microenvironment-responsive nanoparticles for gene delivery. Biomaterials. 2013;34(21):5294–5302.
15. Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 1989;49(16):4373–4384.
16. Roy CR, Salcedo SP, Gorvel JP. Pathogen-endoplasmic-reticulum interactions: in through the out door. Nat Rev Immunol. 2006;6(2): 136–147.
17. Luzio JP, Rous BA, Bright NA, Pryor PR, Mullock BM, Piper RC. Lysosome-endosome fusion and lysosome biogenesis. J Cell Sci. 2000;113 Pt 9:1515–1524.
18. Ciechanover A. Intracellular protein degradation: from a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Differ. 2005;12(9): 1178–1190.
19. Torchilin VP. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm Biopharm. 2009;71(3):431–444.
20. ®20 derivatives enable the formation of efficient pH-sensitive drug delivery vehicles for human hepatoblastoma. Bioorg Med Chem Lett. 2010;20(10): 3021–3025.
21. Matsui S, Matsumoto H, Sonoda Y, et al. Glycyrrhizin and related compounds down-regulate production of inflammatory chemokines IL-8 and eotaxin 1 in a human lung fibroblast cell line. Int Immunopharmacol. 2004;4(13):1633–1644.
22. Genovese T, Menegazzi M, Mazzon E, et al. Glycyrrhizin reduces secondary inflammatory process after spinal cord compression injury in mice. Shock. 2009;31(4):367–337.
23. Paolino D, Lucania G, Mardente D, Alhaique F, Fresta M. Ethosomes for skin delivery of ammonium glycyrrhizinate: in vitro percutaneous permeation through human skin and in vivo anti-inflammatory activity on human volunteers. J Control Release. 2005;106(1–2):99–110.
24. Carafa M, Santucci E, Alhaique F, et al. Preparation and properties of new unilamellar non-ionic/ionic surfactant vesicles. Int J Pharm. 1998;160(1):51–59.
25. Di Marzio L, Marianecci C, Cinque B, et al. pH-sensitive non-phospholipid vesicle and macrophage-like cells: binding, uptake and endocytotic pathway. Biochem Biophys Acta. 2008;1778(12):2749–2756.
26. Carafa M, Santucci E, Lucania G. Lidocaine-loaded non-ionic surfactant vesicles: characterization and in vitro permeation studies. Int J Pharm. 2002;231(1):21–32.
27. ®and ultradeformable liposomes containing a bilayer fluidizing agent. Colloids Surf B Biointerfaces. 2009;72(1):155–160.
28. Ho NFH, Ganesan MG, Weiner ND, et al. Mechanism of topical delivery of liposomally entrapped drugs. J Control Release. 1985;2(1):61–65.
29. Marianecci C, Paolino D, Celia C, et al. Non-ionic surfactant vesicles in pulmonary glucocorticoid delivery: characterization and interaction with human lung fibroblasts. J Control Release. 2010;147(1):127–135.
30. Papini S, Cecchetti D, Campani D, et al. Isolation and clonal analysis of human epidermal keratinocyte stem cells in long-term culture. Stem Cells. 2003;21(4):481–494.
31. Paolino D, Cosco D, Cilurzo F, et al. Improved in vitro and in vivo collagen biosynthesis by asiaticoside-loaded ultradeformable vesicles. J Control Release. 2012;162(1):143–151.
32. Marianecci C, Rinaldi F, Mastriota M, et al. Anti-inflammatory activity of novel ammonium glycyrrhizinate/niosomes delivery system: human and murine models. J Control Release. 2012;164(1):17–25.
33. Colucci M, Maione F, Bonito MC, Piscopo A, Di Giannuario A, Pieretti S. New insights of dimethyl sulphoxide effects (DMSO) on experimental in vivo models of nociception and inflammation. Pharmacol Res. 2008;57(6):419–425.
34. Pieretti S, Di Giannuario A, De Felice M, Perretti M, Cirino G. Stimulus-dependent specificity for annexin 1 inhibition of the inflammatory nociceptive response: the involvement of the receptor for formylated peptides. Pain. 2004;109(1):52–63.
35. Marianecci C, Rinaldi F, Di Marzio L, et al. Interaction of pH-sensitive non-phospholipid liposomes with cellular mimetic membranes. Biomed Microdevices. 2013;15(2):299–309.
36. Wang M, Yuan Y, Gao Y, et al. Preparation and characterization of 5-fluorouracil pH-sensitive niosome and its tumor-targeted evaluation: in vitro and in vivo. Drug Dev Ind Pharm. 2012;38(9):1134–1141.
37. Carafa M, Marianecci C, Rinaldi F, Santucci E, Tampucci S, Monti D. Span and Tween neutral and pH-sensitive vesicles: characterization and in vitro skin permeation. J Liposome Res. 2009;19(4):332–340.
38. Sinico C, Fadda AM. Vesicular carriers for dermal drug delivery. Expert Opin Drug Deliv. 2009;6(8):813–825.
39. Manconi M, Sinico C, Valenti D, Loy G, Fadda AM. Niosomes as carriers for tretinoin. I. Preparation and properties. Int J Pharm. 2002;234(1–2):237–248.
40. [No authors listed]. CFR Parts 182 and 184 GRAS status of licorice, (Glycyrrhiza), ammoniated glycyrrhizin and monoammonium glycyrrhizinate. Fed Regist. 1985;50:21043–21044.
41. Commission Decision of February 23, 1999 adopting a register of flavouring substances used in or on foodstuffs drawn up in application of Regulation (EC) No 2232/96 of the European Parliament and of the Council of October 28, 1996 (notified under number C(1999) 399) (text with EEA relevance) (1999/217/EC). Official Journal of the European Communities. 1999;L084:1-74. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:1999:084:0001:0137:EN:PDF. Accessed January 6, 2014.
42. Cosmetic Ingredient Review Expert Panel. Final report on the safety assessment of glycyrrhetinic acid, potassium glycyrrhetinate, disodium succinoyl glycyrrhetinate, glyceryl glycyrrhetinate, glycyrrhetinyl stearate, stearyl glycyrrhetinate, glycyrrhizic acid, ammonium glycyrrhizate, dipotassium glycyrrhizate, disodium glycyrrhizate, trisodium glycyrrhizate, methyl glycyrrhizate, and potassium glycyrrhizinate. Int J Toxicol. 2007;26 Suppl 2:79–112.
43. Wu Y, Yang W, Wang C, Hu J, Fu S. Chitosan nanoparticles as a novel delivery system for ammonium glycyrrhizinate. Int J Pharm. 2005;295(1–2):235–245.
44. Casals E, Galán AM, Escolar G, Gallardo M, Estelrich J. Physical stability of liposomes bearing hemostatic activity. Chem Phys Lipids. 2003;125(2):139–146.
45. Karmali PP, Simberg D. Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. Expert Opin Drug Deliv. 2011;8(3):343–357.
46. Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 2001;47(1):3–19.
47. Lemarchand C, Couvreur P, Vauthier C, Costantini D, Gref R. Study of emulsion stabilization by graft copolymers using optical analyzer Turbiscan. Int J Pharm. 2003;254(1):77–82.
48. Daoud-Mahammed S, Couvreur P, Gref R. Novel self-assembling nanogels: stability and lyophilisation studies. Int J Pharm. 2007; 332(1–2):185–191.
49. ®containing linoleic acid: physicochemical and technological features of topical drug delivery carriers for the potential treatment of melasma disorders. Biomed Microdevices. 2012;14(1):119–130.
50. Mengual O, Meunier G, Cayré I, Puech K, Snabre P. Characterization of instability of concentrated dispersions by new optical analyzer: the TURBISCAN MA 1000. Colloids and Surfaces A. 1999;152(1–2):111–123.
51. Mengual O, Meunier G, Cayré I, Puech K, Snabre P. TURBISCAN MA 2000: multiple light scattering measurement for concentrated emulsion and suspension instability analysis. Talanta. 1999;50(20):445–456.
52. Buron H, Mengual O, Meunier G, et al. Optical characterization of concentrated dispersions: applications and laboratory analysis and on line process to monitoring and control. Polym Int. 2004;53(9): 1205–1209.
53. Paolino D, Muzzalupo R, Ricciardi A, et al. In vitro and in vivo evaluation of Bola-surfactant containing niosomes for transdermal delivery. Biomed Microdevices. 2007;9(4):421–433.
54. Fattal E, Rojas J, Roblot-Treupel L, et al. Ampicillin-loaded liposomes and nanoparticles: comparison of drug loading, drug release and in vitro antimicrobial activity. J Microencapsul. 1991;8(1):29–36.
55. Araújo J, Garcia mL, Mallandrich M, et al. Release profile and transscleral permeation of triamcinolone acetonide loaded nanostructured lipid carriers (TA-NLC): in vitro and ex vivo studies. Nanomedicine. 2012;8(6):1034–1041.
56. Xu Y, Jia Y, Wang Z, et al. Mathematical modelling and finite element simulation of slow release of drugs using hydrogels as carriers with various drug concentration distributions. J Pharm Sci. 2013;102(5): 1532–1543.
57. Fiume Z. Final report on the safety assessment of lecithin and hydrogenated lecithin. Int J Toxicol. 2001;20 Suppl 1:21–45.
58. Szolcsányi J, Pintér E, Helyes Z, et al. Inhibition of the function of TRPV1-expressing nociceptive sensory neurons by somatostatin 4 receptor agonism: mechanism and therapeutical implications. Curr Top Med Chem. 2011;11(17):2253–2263.
59. Schlosburg JE, Kinsey SG, Lichtman AH. Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation. AAPS J. 2009;11(1):39–44.
60. Lanigan RS, Yamarik TA, Cosmetic Ingredients Review Expert Panel. Final report on the safety assessment of PEG-6, 8, and 20 sorbitan beeswax. Int J Toxicol. 2001;20 Suppl 4:27–38.
61. Carmo VA, Ferrari CS, Reis EC, et al. Biodistribution study and identification of inflammation sites using 99mTc-labelled stealth pH-sensitive liposomes. Nucl Med Commun. 2008;29(1):33–38.
62. ®and ultradeformable liposomes containing a bilayer fluidizing agent. Colloids Surf B Biointerfaces. 2009;72(1):155–160.
63. Caracciolo G, Pozzi D, Capriotti AL, et al. Factors determining the superior performance of lipid/DNA/protammine nanoparticles over lipoplexes. J Med Chem. 2011;54(12):4160–4171.
64. Paolino D, Lucania G, Mardente D, Alhaique F, Fresta M. Ethosomes for skin delivery of ammonium glycyrrhizinate: in vitro percutaneous permeation through human skin and in vivo anti-inflammatory activity on human volunteers. J Control Release. 2005;106(1–2): 99–110.
65. Marianecci C, Rinaldi F, Mastriota M, et al. Anti-inflammatory activity of novel ammonium glycyrrhizinate/niosomes delivery system: human and murine models. J Control Release. 2012;164(1):17–25.
66. Ho NFH, Ganesan MG, Weiner ND, et al. Mechanism of topical delivery of liposomally entrapped drugs. J Control Release. 1985;2(1):61–65.
67. Marianecci C, Paolino D, Celia C, et al. Non-ionic surfactant vesicles in pulmonary glucocorticoid delivery: characterization and interaction with human lung fibroblasts. J Control Release. 2010;147(1):127–135.
68. Papini S, Cecchetti D, Campani D, et al. Isolation and clonal analysis of human epidermal keratinocyte stem cells in long-term culture. Stem Cells. 2003;21(4):481–494.